Loading...
Uterine fibroids (the most common indication for hysterectomy) occur in one third of reproductive-age women. In two manufacturer-sponsored trials, European researchers assessed the efficacy of oral ulipristal acetate (UA) — a selective progesterone-receptor modulator — for treating women in whom surgery for symptomatic fibroids was planned. (UA is currently marketed as ella in the U.S. for emergency contraception [JW Womens Health Jan 12 2012].) The first study was a placebo-controlled trial of two different doses of UA; the second was a noninferiority trial designed to compare UA with monthly injections of leuprolide, a gonadotropin-releasing hormone agonist. In both trials, study drugs were administered for 13 weeks, at which time surgery…